Hugo et al. [26] reported that responding melanoma patients have more BRCA2 mutations while nonresponding patients have fewer mutations (P = 0.002) upon ICI treatment, but the mechanisms are still puzzling. The gene discussed is BRCA2; the disease is melanoma.